左氧氟沙星在重症社区获得性肺炎患者中的药物动力学研究

摘要/Abstract

摘要： 目的: 比较左氧氟沙星治疗重症肺炎的不同用药方案的药物动力学差异,为临床合理用药提供依据。方法: 24例成人重症社区获得性肺炎且正在接受机械通气的患者分为两组(n=12),分别每日1次或2次静脉滴注左氧氟沙星 500 mg,同时每日滴注1次拉维酸 1 g,连续静脉滴注 10 d,经过 2 d 的治疗达到稳定状态后利用高效液相色谱法测定血浆和上皮细胞衬液中左氧氟沙星的浓度,并比较两组间药动学参数。结果: 每日滴注1次的患者,左氧氟沙星的血浆值浓度和上皮细胞衬液浓度分别为(12.6±2.3) mg/L 和(11.9±2.7) mg/L,每日滴注2次的患者分别为(19.7±1.8) mg/L 和(17.8±1.7) mg/L,这表明左氧氟沙星在肺组织的穿透率都大于100%。每日滴注1次和2次的患者全身暴露浓度(AUC_24h)分别为(151.2±12.8) mg·h·L^-1 和(208.6±15.1) mg·h·L^-1,均高于常见重症肺炎致病菌的最小抑菌浓度(MIC)。每日滴注1次组的治疗成功率为83%(10/12),每日滴注2次组为92%(11/12),无统计学差异(P>0.05)。结论: 对因重症社区获得性肺炎接受机械通气的危重患者,每日静脉滴注500 mg左氧氟沙星1次或2次均能达到最小的抑菌浓度。

关键词: 左氧氟沙星, 药物动力学, 社区获得性肺炎, 重症监护

Abstract: AIM: To compare the different medication regimens of levofloxacin in treatment of community-acquired pneumonia and provide evidence for clinical rational drug use.METHODS: Twenty-four adult patients with severe community-acquired pneumonia and receiving mechanical ventilation were assigned randomly into 2 groups (n=12) received 1-hour intravenous infusion of levotloxacin 500 mg once or twice daily respectively. The levotloxacin concentrations at steady-state in plasma and epithelial lining fluid were determined with high-performance liquid chromatography after 2 days of therapy. The pharmacokinetics was calculated and compared.RESULTS: Levotloxacin concentrations in plasma and epithelial lining fluid peak were (12.6±2.3) mg/L and (11.9±2.7) mg/L respectively in the once-daily group and(19.7±1.8) mg/L and(17.8±1.7)mg/L in the twice-daily group, showing pulmonary penetration percentage >100% in both groups. The total body exposure (AUC_24h)in the once-daily and twice-daily group was(151.2±12.8) mg·h·L^-1 and(208.6±15.1) mg·h·L^-1 respectively, each higher than the minimal inhibitory concentration for severe pneumonia. The treatment success rate in the once-daily and twice-daily group was 83%(10/12)and 92%(11/12)with no significant difference(P>0.05).CONCLUSION: For critically ill patients with severe community-acquired pneumonia and receiving mechanical ventilation, the administration of intravenous levofloxacin 500 mg once and twice daily all can reach the minimal inhibitory concentration.

Key words: Levofloxacin, Pharmacokinetics, Community-acquired pneumonia, Intensive care

中图分类号:

R969

叶英. 左氧氟沙星在重症社区获得性肺炎患者中的药物动力学研究[J]. 中国临床药理学与治疗学, 2013, 18(6): 661-668.

YE Ying. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(6): 661-668.

参考文献

[1] Ferrara AM.A brief review of moxifloxacin in the treatment of elderly patients withcommunity-acquired pneumonia (CAP) [J].Clin Interv Aging, 2007 2(2):179-187.
[2] Blasi F, Aliberti S, Tarsia P, et al. Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis[J]. Chron Obstruct Pulmon Dis, 2007, 2 (1): 27-31.
[3] Lodise T,Graves J,Miller C,et al. Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients[J]. Pharmacotherapy, 2007, 27(11):1498-1505.
[4] Giannarini G,Mogorovich A,Valent F, et al. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial[J].Chemother, 2007, 19(3):304-308.
[5] Boselli E, Breilh D, Rimmele T, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia[J]. Intensive Care Med, 2004,30(8):989-991.
[6] Benko R, Matuz M,Doro P, et al. Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia[J]. Antimicrob Agents, 2007, 30(2): 162-168.
[7] Hori S. PK/PD analysis and proper dosage of antimicrobial agents for effective and safe treatment of infectious diseases[J]. Yakugaku Zasshi, 2007,127(6): 931-937.
[8] Nielsen EI, Viberg A, Lowdin E, et al. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments[J]. Antimicrob Agents Chemother, 2007, 51(1): 128-136.
[9] Bao D,Truong TT,Renick PJ, et al. Simultaneous determination of rifampicin and levofloxacin concentrations in catheter segments from a mouse model of a device-related infection by liquid chromatography/electrospray ionization tandem mass spectrometry[J]. Pharm Biomed Anal,2008,46(4): 723-727.
[10]Zhou ZL, Yang M, Yu XY, et al. A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies[J]. Biomed Chromatogr, 2007, 21(10): 1045-1051.
[11]Filetm JR, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia[J]. Chest ,2004,125(32):1888-1901.
[12]Yamazaki K, Ogura S, Ishizaka A, et al. Bronchoscopic microsampling method for meacuring drug concentration in epithelial lining fluid[J]. Am J Respir Crit Care Med, 2003,168(13):1304-1307.
[13]王静,王俊平,张依山,等.左氧氟沙星临床验证[J].中国新药与临床杂志,2003,23(4):109-112.

[1]	党子龙, 刘海洋, 张扬帆, 刘金凤, 张天为, 李斌, 郭鸿, 成文媛, 许晓辉, 李一乐, 魏玉辉, 武新安. 肾功能亢进ICU患者的抗菌药物给药方案调整策略研究进展[J]. 中国临床药理学与治疗学, 2023, 28(5): 561-571.
[2]	李筱旻, 金浩, 周文智, 杨汉跃, 邹婷, 郭洁, 徐平声. 盐酸二甲双胍缓释片在健康人体的生物等效性研究[J]. 中国临床药理学与治疗学, 2021, 26(4): 408-413.
[3]	李小宁, 余潇, 黄晨蕾, 曹若楠, 李婕, 朱国萍. 氨溴索联合左氧氟沙星对肺炎克雷伯菌生物膜抑制和清除能力的研究[J]. 中国临床药理学与治疗学, 2021, 26(10): 1103-1110.
[4]	李力，李贺，刘杏娥，魏楠. LC-MS/MS法测定肿瘤患者血浆中阿帕替尼浓度及其临床应用[J]. 中国临床药理学与治疗学, 2018, 23(7): 790-795.
[5]	李贺，陈国耘，沈琦，黄越，朱逢佳，刘炜，李力. LC-MS/MS法测定人血浆中西格列汀浓度及其药物动力学研究[J]. 中国临床药理学与治疗学, 2016, 21(10): 1144-1148.
[6]	朱文静, 崔卫华, 王少华, 张媛媛, 高纪军. 莫西沙星对社区获得性肺炎治疗作用的研究进展[J]. 中国临床药理学与治疗学, 2015, 20(5): 597-600.
[7]	程茂良, 王珏. MDR1基因多态性对替米沙坦血药浓度和药动力学影响研究[J]. 中国临床药理学与治疗学, 2013, 18(6): 643-648.
[8]	景贤, 王医成, 欧阳冬生, 陈尧, 周淦, 阳国平, 周宏灏, 谭志荣. 高效液相色谱串联质谱法测定人血浆中吲达帕胺浓度及生物等效性研究[J]. 中国临床药理学与治疗学, 2012, 17(10): 1157-1162.
[9]	李进文. 一室模型药物吸收计算的概率论法[J]. 中国临床药理学与治疗学, 2012, 17(1): 59-63.
[10]	杜婷, 孙荣进, 徐国良, 李冰涛, 黄丽萍, 李佳. 药理效应法测定参附注射液药动学参数的研究[J]. 中国临床药理学与治疗学, 2012, 17(1): 69-72.
[11]	高芬, 关巍, 久太. 高原环境肺功能改变对复方新诺明药物动力学的影响[J]. 中国临床药理学与治疗学, 2009, 14(7): 790-793.
[12]	崔俊昌, 刘又宁, 王睿, 童卫杭, 梁蓓蓓. 左氧氟沙星药代动力学/药效动力学参数与金黄色葡萄球菌耐药的相关性研究[J]. 中国临床药理学与治疗学, 2007, 12(9): 989-992.
[13]	李朝霞, 刘又宁, 王睿, 童卫杭, 程仕虎. 左氧氟沙星联合万古霉素缩小金黄色葡萄球菌耐药突变选择窗的初步研究[J]. 中国临床药理学与治疗学, 2007, 12(8): 911-914.
[14]	储继红, 居文政, 许美娟, 吴婷, 魏熹, 谈恒山, 蒋萌, 熊宁宁. 盐酸左氧氟沙星软胶囊、硬胶囊和片剂的人体药动学研究[J]. 中国临床药理学与治疗学, 2007, 12(6): 710-713.
[15]	崔俊昌, 刘又宁, 王睿, 童卫杭, 李朝霞. 左氧氟沙星对兔组织笼金黄色葡萄球菌感染的疗效研究[J]. 中国临床药理学与治疗学, 2007, 12(3): 291-294.